Regulation of plasma fructose and mortality in mice by the aldose reductase inhibitor lidorestat

Journal of Pharmacology and Experimental Therapeutics

Volumn 328, Issue 2, 2009, Pages 496-503

  Noh, Hye Lim ^a   Hu, Yunying ^a   Park, Tae Sik ^a   DiCioccio, Thomas ^b   Nichols, Andrew J ^c   Okajima, Kazue ^a   Homma, Shunichi ^a   Goldberg, Ira J ^a,d  

^a College of Physicians and Surgeons ^*  (United States)

^b The Institute for Diabetes Discovery   (United States)

^c Alinea Pharmaceutical   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE REDUCTASE; FRUCTOSE; HUMAN ALDEHYDE REDUCTASE; LIDORESTAT; LOW DENSITY LIPOPROTEIN RECEPTOR; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL DIET; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; MALE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; STREPTOZOCIN DIABETES; TRANSGENIC MOUSE;

ALDEHYDE REDUCTASE; ANIMALS; BIOLOGICAL PROCESSES; BLOOD; BLOOD GLUCOSE; ENZYME INHIBITORS; FRUCTOSE; HUMANS; INDOLEACETIC ACIDS; MICE; MICE, KNOCKOUT; MORTALITY; STREPTOZOCIN; THIAZOLES;

EID: 59649120038     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.136283     Document Type: Article

References (38)

1. Berg JM, Tymoczko TJ, and Stryer L (2001) Biochemistry, W.H. Freeman, New York.
2. Berti JA, Salerno AG, Bighetti EJ, Casquero AC, Boschero AC, and Oliveira HC (2005) Effects of diabetes and CETP expression on diet-induced atherosclerosis in LDL receptor-deficient mice. APMIS 113:37-44.
3. Bunn HF and Higgins PJ (1981) Reaction of monosaccharides with proteins: possible evolutionary significance. Science 213:222-224.
4. Cai L, Li W, Wang G, Guo L, Jiang Y, and Kang YJ (2002) Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes 51:1938-1948.
5. Cai L, Wang Y, Zhou G, Chen T, Song Y, Li X, and Kang YJ (2006) Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy. J Am Coll Cardiol 48:1688-1697.
6. Collins AR, Meehan WP, Kintscher U, Jackson S, Wakino S, Noh G, Palinski W, Hsueh WA, and Law RE (2001) Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 21:365-371.
7. Cui XL, Jiang L, and Ferraris RP (2003) Regulation of rat intestinal GLUT2 mRNA abundance by luminal and systemic factors. Biochim Biophys Acta 1612:178-185.
8. de Walque S, Opperdoes FR, and Michels PA (1999) Cloning and characterization of Leishmania mexicana fructose-1,6-bisphosphate aldolase. Mol Biochem Parasitol 103:279-283.
9. Finck BN, Han X, Courtois M, Aimond F, Nerbonne JM, Kovacs A, Gross RW, and Kelly DP (2003) A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci U S A 100:1226-1231.
10. Flarsheim CE, Grupp IL, and Matlib MA (1996) Mitochondrial dysfunction accompanies diastolic dysfunction in diabetic rat heart. Am J Physiol 271:H192-H202.
11. Ganea E and Harding JJ (1995) Molecular chaperones protect against glycation-induced inactivation of glucose-6-phosphate dehydrogenase. Eur J Biochem 231:181-185.
12. Ganea E and Harding JJ (2005) Trehalose and 6-aminohexanoic acid stabilize and renature glucose-6-phosphate dehydrogenase inactivated by glycation and by guanidinium hydrochloride. Biol Chem 386:269-278.
13. Goldberg IJ and Dansky HM (2006) Diabetic vascular disease: an experimental objective. Arterioscler Thromb Vasc Biol 26:1693-1701.
14. Held C, Gerstein HC, Yusuf S, Zhao F, Hilbrich L, Anderson C, Sleight P, and Teo K (2007) Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation 115:1371-1375.
15. Hwang YC, Kaneko M, Bakr S, Liao H, Lu Y, Lewis ER, Yan S, Ii S, Itakura M, Rui L, et al. (2004) Central role for aldose reductase pathway in myocardial ischemic injury. FASEB J 18:1192-1199.
16. Hwang YC, Sato S, Tsai JY, Yan S, Bakr S, Zhang H, Oates PJ, and Ramasamy R (2002) Aldose reductase activation is a key component of myocardial response to ischemia. FASEB J 16:243-245.
17. Kanter JE, Johansson F, LeBoeuf RC, and Bornfeldt KE (2007) Do glucose and lipids exert independent effects on atherosclerotic lesion initiation or progression to advanced plaques? Circ Res 100:769-781.
18. Kawasaki T, Akanuma H, and Yamanouchi T (2002) Increased fructose concentrations in blood and urine in patients with diabetes. Diabetes Care 25:353-357.
19. Lin RY, Choudhury RP, Cai W, Lu M, Fallon JT, Fisher EA, and Vlassara H (2003) Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 168:213-220.
20. Merat S, Casanada F, Sutphin M, Palinski W, and Reaven PD (1999) Western-type diets induce insulin resistance and hyperinsulinemia in LDL receptor-deficient mice but do not increase aortic atherosclerosis compared with normoinsulinemic mice in which similar plasma cholesterol levels are achieved by a fructose-rich diet. Arterioscler Thromb Vasc Biol 19:1223-1230.
21. Nakano I, Tsugawa T, Shinohara R, Watanabe F, Fujita T, Nagata M, Kato T, Himeno Y, Kobayashi T, Fujiwara K, et al. (2003) Urinary sorbitol measurement and the effect of an aldose reductase inhibitor on its concentration in the diabetic state. J Diabetes Complications 17:337-342.
22. Noh HL, Okajima K, Molkentin JD, Homma S, Homma S, and Goldberg IJ (2006) Acute lipoprotein lipase deletion in adult mice leads to dyslipidemia and cardiac dysfunction. Am J Physiol Endocrinol Metab 291:E755-E760.
23. Pitkänen E (1996) Mannose, mannitol, fructose and 1,5-anhydroglucitol concentrations measured by gas chromatography/mass spectrometry in blood plasma of diabetic patients. Clin Chim Acta 251:91-103.
24. Raman P, Krukovets I, Marinic TE, Bornstein P, and Stenina OI (2007) Glycosylation mediates up-regulation of a potent antiangiogenic and proatherogenic protein, thrombospondin-1, by glucose in vascular smooth muscle cells. J Biol Chem 282:5704-5714.
25. Ramana KV, Willis MS, White MD, Horton JW, DiMaio JM, Srivastava D, Bhatnagar A, and Srivastava SK (2006) Endotoxin-induced cardiomyopathy and systemic inflammation in mice is prevented by aldose reductase inhibition. Circulation 114:1838-1846.
26. Renard CB, Kramer F, Johansson F, Lamharzi N, Tannock LR, von Herrath MG, Chait A, and Bornfeldt KE (2004) Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. J Clin Invest 114:659-668.
27. Reusch JE (2003) Diabetes, microvascular complications, and cardiovascular complications: what is it about glucose? J Clin Invest 112:986-988.
28. Ruderman NB, Williamson JR, and Brownlee M (1992) Glucose and diabetic vascular disease. FASEB J 6:2905-2914.
29. Russell LK, Finck BN, and Kelly DP (2005) Mouse models of mitochondrial dysfunction and heart failure. J Mol Cell Cardiol 38:81-91.
30. Siegel TW, Smith SR, Ellery CA, Williamson JR, and Oates PJ (2000) An enzymatic fluorometric assay for fructose. Anal Biochem 280:329-331.
31. Suárez G, Rajaram R, Oronsky AL, and Gawinowicz MA (1989) Nonenzymatic glycation of bovine serum albumin by fructose (fructation): comparison with the Maillard reaction initiated by glucose. J Biol Chem 264:3674-3679.
32. Takuma S, Suehiro K, Cardinale C, Hozumi T, Yano H, Shimizu J, Mullis-Jansson S, Sciacca R, Wang J, Burkhoff D, et al. (2001) Anesthetic inhibition in ischemic and nonischemic murine heart: comparison with conscious echocardiographic approach. Am J Physiol Heart Circ Physiol 280:H2364-H2370.
33. Tanaka Y, Konno N, and Kako KJ (1992) Mitochondrial dysfunction observed in situ in cardiomyocytes of rats in experimental diabetes. Cardiovasc Res 26:409-414.
34. Teupser D, Persky AD, and Breslow JL (2003) Induction of atherosclerosis by low-fat, semisynthetic diets in LDL receptor-deficient C57BL/6J and FVB/NJ mice: comparison of lesions of the aortic root, brachiocephalic artery, and whole aorta (en face measurement). Arterioscler Thromb Vasc Biol 23:1907-1913.
35. Van Zandt MC, Jones ML, Gunn DE, Geraci LS, Jones JH, Sawicki DR, Sredy J, Jacot JL, Dicioccio AT, Petrova T, et al. (2005) Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. J Med Chem 48:3141-3152.
36. Vikramadithyan RK, Hu Y, Noh HL, Liang CP, Hallam K, Tall AR, Ramasamy R, and Goldberg IJ (2005) Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice. J Clin Invest 115:2434-2443.
37. Yamaoka T, Nishimura C, Yamashita K, Itakura M, Yamada T, Fujimoto J, and Kokai Y (1995) Acute onset of diabetic pathological changes in transgenic mice with human aldose reductase cDNA. Diabetologia 38:255-261.
38. Yoshii H, Uchino H, Ohmura C, Watanabe K, Tanaka Y, and Kawamori R (2001) Clinical usefulness of measuring urinary polyol excretion by gas-chromatography/mass-spectrometry in type 2 diabetes to assess polyol pathway activity. Diabetes Res Clin Pract 51:115-123.